Clinical trials: Recurrent Head and Neck Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Oral Cavity
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan.
- Trial name
- NCT04387682
- Testing
- β-glucan
- Where
- Taiwan
- Volunteers
- 130 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Neoplasms
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.
- Trial name
- NCT03020823
- Testing
- SCB01A
- Where
- 4 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back.
- Conditions
- Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Trial name
- NCT02068157
- Testing
- Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer
Biomarkers in Patients With Head and Neck Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.
- Trial name
- NCT01466257
- Testing
- cetuximab, cisplatin, DNA analysis
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel…
- Trial name
- NCT02051751
- Testing
- BYL719, Paclitaxel
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Cancer
Study of Sorafenib/Cetuximab in Head and Neck Cancer
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00815295
- Testing
- Sorafenib, Cetuximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence
Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck
Adenoid cystic carcinomas are rare cancers of the salivary glands. These cancers are treated with curative surgery, often followed by radiation therapy.
- Conditions
- Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease
- Trial name
- ZANACC (NCT07682675)
- Testing
- Zanzalintinib
- Where
- 2 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
Colorectal Cancer, Esophageal Cancer
Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00628368
- Testing
- Gene expression analysis
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive
- Trial name
- NCT02955290
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
Nasopharyngeal Carcinoma
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this trial is to examine the role of camrezlizumab in addition to carbon-ion radiotherapy (CIRT) for patients with locally recurrent nasopharyngeal carcinoma.
- Trial name
- NCT04143984
- Testing
- Induction chemotherapy, Carbon-ion radiotherapy, Camrelizumab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Head and Neck Cancer
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00757549
- Testing
- cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Head and Neck Cancer
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have advanced head…
- Trial name
- NCT00005035
- Testing
- oxaliplatin
- Where
- 11 sites in United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body.
- Conditions
- Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT00859937
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 34 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Immunotherapy, Head and Neck Neoplasms
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
This is a phase IB/II trial to examine feasibility and safety of checkpoint blockade (aPD1 with or without aCTLA4) neoadjuvant to standard of care (SOC) in advanced stage head and neck squamous cell carcinoma (HNSCC), a patient…
- Trial name
- IMCISION (NCT03003637)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT07791745
- Testing
- Enlituo® + Anyouping® + PBC
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Esophageal Cancer, Gastric Cancer
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005599
- Testing
- bryostatin 1, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.